Physician profile
Priya Mathur
NPI 1346407418
$2,670.38
in general payments reported to CMS, 2019-2025
26 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.90 · 2023: $932 · 2024: $856 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.75 |
| Education | $153.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $508.89 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $288.44 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $255.70 | 2023-2025 | |
| Abbvie INC. | $234.56 | 2023-2025 | |
| Astellas Pharma US INC | $202.35 | 2023-2024 | Veozah, Xtandi |
| Amgen INC. | $197.71 | 2024-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $136.27 | 2024-2025 | |
| Glaxosmithkline, LLC. | $119.99 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $97.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.79 | 2024-2025 | Gilotrif, Jardiance |
| Otsuka America Pharmaceutical, INC. | $92.32 | 2023-2025 | Rexulti |
| Hologic Sales and Service, LLC | $57.76 | 2024-2025 | Aptima |
| Astrazeneca Pharmaceuticals LP | $54.90 | 2023-2024 | Farxiga, Airsupra |
| Horizon Therapeutics Plc | $51.87 | 2023 | Krystexxa |
| Seqirus USA INC | $50.19 | 2023-2025 | Fluad Quadrivalent, Flucelvax, Fluad |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.21 | 2023 | Xifaxan |
| Radius Health, INC. | $27.39 | 2023 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $21.84 | 2023 | Cuvitru |
| Novavax INC | $21.62 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Eisai INC. | $20.90 | 2022 | |
| Lundbeck LLC | $19.80 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $18.45 | 2025 | Jornay Pm |
| Tactile Systems Technology INC | $15.23 | 2023 | Entre Plus, Flexitouch Plus |
| Phathom Pharmaceuticals, INC. | $15.14 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $14.73 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.99 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.